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Synthetic approaches towards avibactam and other 
diazabicyclooctane β-lactamase inhibitors 
Laure Peilleron,a Kevin Cariou,*a,b  
Avibactam is a non β-lactam β-lactamase inhibitor that has recently been approved in association with a β-lactam antibiotic 
for the treatment of severe infections caused by otherwise resistant bacteria. Its therapeutic success encouraged the 
development of many congeners based on its particular diazabicyclooctane scaffold. This review presents a detailed 
overview of the synthetic strategies that have been implemented to acces these complex bicyclic compounds with a 
particular focus on those that are currently on the market or in clinical trials. 
1 Introduction 
The discovery of penicillin G by Sir Alexander Fleming in 1928 
was the beginning of a “Golden Age” for antibiotics, especially 
between the 40s and the 70s.1 However, their over-, and 
sometimes unwise, utilization has led to an increased apparition 
and dissemination of resistance phenomena in bacteria, that 
led the WHO to warn against the imminent beginning of a “post-
antibiotic era”.2 In particular, many resistance mechanisms 
target β-lactam antibiotics, which are among the most 
prescribed worldwide, such as the production of β-lactamase 
enzymes that hydrolyze the β-lactam nucleus, thus effectively 
inactivating the antibiotic. In order to overcome these 
resistances, two strategies can be envisioned.3 One is to 
develop new generations of antibiotics. For example, after 
penicillins, cephalosporins, carbapenems and monobactams 
were successively developed (Figure 1A). Yet, the 
commercialization of these novel antibiotics was systematically 
followed by the apparition of resistances and the current 
antibiotic pipeline contains only a few new β-lactam 
compounds, all of them being variants of existing molecules 
(e.g. cefiderocol4,5 and BAL300726 that both have a siderophore 
attached to a known scaffold). Another approach is to fight 
these resistances, by developing small molecules that, in 
combination with an antibiotic can preserve or restore its 
activity,7 in particular by inhibiting β-lactamases (BLs).8 While 
most research had been restricted to β-lactam-based inhibitor, 
such as clavulanic acid, non-β-lactam-based inhibitors are now 
actively studied (Figure 1B). Since 2012, several new broad-
spectrum inhibitors of serine β-lactamases (SBLs) of classes A 
and C have emerged.9 Notably, the diazabicyclooctane (DBO)10 
avibactam11,12 and the boronic ester vaborbactam (RPX7009)13 
were recently approved by the FDA in combination with 
ceftazidime and meropenem, respectively. 
Figure 1 Representative examples of β-lactam antibiotics and β-lactamase inhibitors (in bold: year on the market; in italic: year of 
resistance apparition). 
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The DBO family is of particular interest as several other 
congeners such as nacubactam,10 zidebactam14 or ETX251415 
are in different stages of preclinical or clinical development and 
a combination of imipenem, cilastatin and relebactam16 
(MK7655) was just approved by the FDA in 2019. 
The aim of this review is to provide the reader with a 
comprehensive overview of the synthetic strategies that have 
been implemented to access β-lactamase inhibitors (BLIs) and 
antibiotics of the DBO family. Because these molecules can only 
be accessed through relatively long and complex multistep 
synthetic sequences, it showcases how innovative and efficient 
organic synthesis17–19 can provide access to an important class 
of therapeutic molecules. As more than 150 patents 
representing more than 3000 molecules can be found from a 
general structural search (this patent literature was reviewed 
and summarized in 201020 and in 201321), an exhaustive 
monograph could not be envisaged and we chose to focus 
mainly on key lead compounds, including FDA approved 
molecules. Derivatives presenting an original way of access will 
also be covered. Finally, the details of the mode of action of 
these compounds will only be briefly presented in the first 
section to provide a reference frame. Readers wishing to have 
more insights on these aspect can refer to the seminal review 
by the group of Schofield: “The road to avibactam: the first 
clinically useful non-β-lactam working somewhat like a β-
lactam” and references therein.12 
2. Mode of action of avibactam 
Since the majority of the mechanistic studies have been carried 
out with avibactam, the mode of action of DBO inhibitors will 
be described with this compound. The inactivation of β-lactam 
antibiotics by SBLs occurs through the hydrolysis of the four-
member amide by an active serine residue of the enzyme. DBOs 
take the place of the antibiotic in the enzyme and the serine 
attacks the carbonyl of the urea. The increased electrophilicity 
of this carbonyl is essentially due to the bicyclic framework, 
whose strained geometry is key for the compound activity. This 
carbamylation reaction leads to rather stable (compared to an 
acyl-enzyme complex) carbamoyl-enzyme complex that 
efficiently block the active site (Scheme 1).11 Moreover, unlike 
β-lactam inhibitors, that can undergo various rearrangements 
and fragmentations after the formation of the acyl-enzyme 
complex, leading to the degradation of the compound, 
avibactam can be regenerated after reacting with the enzyme. 
Since the carbamoyl-enzyme complex is not hydrolyzed, it can 
undergo a slow decarbamylation to revert to avibactam. The 
stabilization of the complex is also due to several secondary 
interactions with the polar residues of the cavity.22 As evidenced 
by a crystal structure of the complex with the CTX-M-15,23 after 
the opening of the cyclic urea, the N-sulfate group remains in 
close vicinity of the ester bond formed with Ser-70. Lastly, the 
primary amide group is located so that it can interact with the 
water molecules that usually trigger the hydrolysis of the acyl-
enzyme complex that would have been formed with a β-lactam. 
These combined effects grant the avibactam-enzyme complex 
an extended half-life time of more than 7 days for TEM-1 and 
P99 β-lactamases, compared to 7 min for clavulanic acid with 
the former and 5 h for tazobactam with the latter. Because of 
this, only 2-5 molecules of avibactam are sufficient to inhibit 1 
enzyme while this ratio is 55:1 for tazobactam against P99 and 
214:1 for clavulanic acid against TEM-1.24 Additionally, several 
DBO derivatives can interact not only with SBLs but also with 
penicillin-binding proteins (PBPs), thus conferring them intrinsic 
antibiotic activities.25 However, they are inactive against 
metallo-β-lactamases (MBLs, class B) that possess zinc atoms in 
the active hydrolytic site, such as New Delhi metallo-beta-
lactamase 1 (NDM-1) or Verona integron-encoded metallo-β-
lactamases (VIM).26 
3. Synthesis of avibactam 
3.1 History. 
Avibactam was discovered in the mid-90s by chemists from 
Hoechst Marion Roussel (HMR). In 1999, HMR became part of 
Aventis and avibactam was first known as AVE1330A. After the 
merger with Sanofi-Synthelabo in 2004, Novexel stemmed out  
Scheme 1 Mechanism of inhibition of the CTX-M-15 β-lactamase by avibactam and stabilization of the carbamoyl-enzyme complex
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to pursue antibacterial researches and avibactam was then 
named NXL104. Novexel was eventually acquired by 
AstraZeneca in 2009. AstraZeneca with Forest Laboratories 
(later bought by Actavis, now Allergan) jointly developed the 
combination of avibactam and ceftazidime which was approved 
by the FDA in 2015 and by the EMA in 2016 under the trade 
names Avycaz® and Zavicefta®. 
3.2 First synthesis. 
The first patents describing the synthesis of avibactam were 
published in 2002 for the international version27 and in 2003 for 
the US version.28 The latter one discloses the original synthesis 
of avibactam (Scheme 2). It is worth mentioning that this patent 
does not give any information concerning the absolute 
configuration of the molecule as only trans and cis are used to 
differentiate the isomers. The synthesis starts from N-Boc-
hydroxy-piperidine 1 (vide infra) which protecting group was 
first swapped from a Boc to a trifluoroacetate in 3 steps to give 
2 with 73% yield (Scheme 2). The trans hydroxylamine was then 
obtained by a triflation/SN2 sequence using O-benzyl-
hydroxylamine to furnish compound 3 with 72% yield. The 
trifluoroacetate group was reductively cleaved with sodium 
borohydride and the resulting free base piperidine 4 was 
isolated with 55% after crystallization of its oxalate salt followed 
by neutralization. The bicyclic derivative 5 was obtained in 89% 
yield after treatment with triphosgene. The allyl group was 
removed by a Pd(0)-catalyzed Tsuji-Trost reaction with sodium 
ethylhexanoate and the resulting carboxylic acid 6 was 
converted into primary amide 7 via the formation of the mixed 
isobutyl anhydride. The hydroxylamine group was deprotected 
by hydrogenolysis of the benzyl group and treatment with SO3-
pyridine complex followed by acidification (of the pyridinium 
salt) gives avibactam. It was then first transformed into its tetra-
t-butylammonium salt 8 before going through a sodium ion-
exchange resin to furnish 9 in 11% overall yield (16 steps). 
Nevertheless, this yield has to be put further into perspective. 
As no indication of the enantiomeric purity is given, one has to 
assume that avibactam was isolated as a racemic mixture. 
Moreover, the synthesis of the key advanced intermediate 1 is 
not described and the inventors mention that it was prepared 
according to the previous work by C. Beyerman & P. Boekee.29 
In this study, diethyl glutamate 10 was first alkylated to give 
triester 11 and the amine was protected as a benzoyl to give 12 
with 70% yield (Scheme 3). A Dieckmann condensation then 
yielded the mixture of regioisomers 13 & 13’ (75% combined) 
that were subjected to acidic conditions to promote a full 
deprotection and a decarboxylation towards 14, (85%) which 
was unfortunately obtained as a racemate.30 
The piperidine was protected as a benzylcarbamate (15) to 
avoid the formation of the trans-hydroxyacid 16 during the 
reduction. Using sodium borohydride, cis-16 was obtained in 
89% yield. The Cbz group was cleaved by treatment of a 
AcOH/HBr mixture to give the hydrobromide salt of the amine, 
which was purified by Amberlite resin treatment to give 17. This 
8 steps sequence leads to cis-5-hydroxypipecolic acid 17 in 39% 
yield, from there, the inventors presumably did a Boc protection 
followed by an esterification to get to key intermediate 1. This 
means that the first synthesis of avibactam (as a racemate) 
effectively required 26 steps, with an overall yield under 4% that 
was not suitable for scale-up purposes. Many improvements 
were then made in order to overcome these limitations, 
although the general strategy was not deeply altered. 
Scheme 2 First racemic synthesis of avibactam  
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Scheme 3 Racemic synthesis of 5-hydroxypipecolic acid 17 and formation of key intermediate 1
3.3 First improvements (Novexel). 
One major improvement brought up by Novexel chemists31 was 
to start the synthesis from commercially available enantiopure 
2-pyrrolidone 18. This bypassed the ten steps necessary to 
reach piperidine 1, thus halving the total number of steps 
needed to make avibactam (Scheme 4). First, γ-lactam 18 was 
subjected to Corey-Chaykovsky-type reaction conditions and 
addition of a sulfonium ylide yielded zwitterionic enolate 19. 
Reaction with lithium chloride under acidic conditions gave an 
intermediate chloro-ketone onto which O-benzylhydroxylamine 
was condensed to furnish oxime 20 as an E/Z mixture. The 
cyclization to piperidine 21 was accomplished by acidic 
treatment, also causing cleavage of the Boc group, followed by 
neutralization. The oxime was then reduced to an 
hydroxylamine that was isolated as its oxalate salt 22 as a 75:25 
mixture of trans and cis isomers with a 65% overall yield. The 
bicyclic core was generated by treatment with triphosgene to 
form urea 23. A strictly controlled (temperature, reaction time, 
pH) hydrolysis of the ester using lithium hydroxide allowed the 
selective saponification of the trans derivative and the isolation 
of solely the corresponding trans carboxylic acid. Primary amide 
7 is then obtained by formation of a pivaloyl anhydride followed 
by treatment with ammonia. The subsequent steps are nearly 
identical to the ones presented in Scheme 2.
Scheme 4 Second synthesis of avibactam by Novexel  
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Scheme 5 Improved synthesis of bicycle 7 from trans piperidine 22 and of avibactam ammonium salt 8 from 7 
After debenzylation by hydrogenolysis, the sulfate group was 
introduced and avibactam was eventually isolated as its sodium 
salt 9. The overall efficiency of the route was greatly improved 
from 26 steps to 15 steps and from less than 4% to 8%. Yet, the 
Process Mass Intensity (PMI) was calculated at 6480 (indicating 
that 1kg of avibactam was produced at the expense of 6480 kg 
of starting materials). As this was still not suitable for industrial 
purposes, further streamlining was needed. Moreover, toxic 
reagents or solvents such as dichloromethane and DMF or 
hazardous reactants such as sodium hydride should ideally be 
avoided and some steps (23 to 7 in particular) were not efficient 
enough.  
3.4 Subsequent improvements (AstraZeneca/Forest). 
First, three key changes were done to optimize the 
transformation of 18 into piperidine 22: potassium tert-
butoxyde was used instead of sodium hydride; the chlorination 
and the formation of the oxime were performed in a one-pot 
fashion; only the final product 22 was purified. This allowed to 
isolate the (S/R) isomer of piperidine 22 with a 56% overall yield 
on a 300 kg scale.32  
Since only the trans isomer of 22 was isolated, the tedious 
selective saponification step could be avoided and amide 24 
was directly obtained in 92% yield by treatment with a 
methanolic solution of ammonia (Scheme 5). A selective Fmoc-
protection of the amine was necessary before activating the 
hydroxylamine with carbonyldiimidazole to give intermediate 
25. The deprotection of the Fmoc group, which triggers the 
cyclization to get bicyclic adduct 7, was achieved with 
diethylamine, which was crystallized after acidic treatment. The 
overall yield of this sequence is 83% (vs 23%, see Scheme 4) and 
it avoids the use of triphosgene. The hydrogenolysis solvent was 
changed to a 1:1 mixture of isopropanol and water (instead of 
DMF/DCM), which lowered the pKa of the resulting 
hydroxylamine. This rendered possible a one-pot 
debenzylation/sulfation by carrying the hydrogenolysis in 
presence of triethylamine and the commercially available 
SO3•NMe3 complex. The ammonium salt 8 was eventually 
isolated in 85% over two steps (vs 55%, see Scheme 4). 
This route only requires 5 steps with isolation and delivers 
avibactam sodium salt in 35% from 2-pyrrolidone 18. The route 
is also safer as many toxic and/or hazardous reagents and 
solvent can be avoided and the PMI was diminished to 526. 
3.5 Alternative route. 
In 2018, the teams of Chen and Wu, described an alternative 
approach to avibactam, starting from ethyl 5-hydroxypicolinate 
hydrochloride 27 (Scheme 6).33 This aromatic starting material 
is first fully reduced, thus avoiding lengthy multistep protocols, 
to directly obtained piperidine 28 with an excellent 97:3 
diasteromeric ratio in favor of the cis isomer. Using a lipase, the 
(S,S) ester 29 can be easily separated from the (R,R) acid 29’ 
after a protection step with a Boc group. The introduction of the 
hydroxylamine group was realized following Aventis protocol 
(see Scheme 2) to give 30 that was converted into primary 
amide 24 (31% yield over 6 steps from 27).  
Scheme 6 Use of lipase catalytic resolution for the synthesis of trans piperidine 24 
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The rest of the synthesis is the same as the AstraZeneca/Forest route 
described by Golden. Avibactam sodium salt could thus be isolated 
with 24% yield over 10 steps on a 400 g scale. 
4. Synthesis of relebactam 
4.1 History. 
Relebactam,34 initially known as MK-7655,16 was developed by 
Merck, taking cues from their own research program on bicyclic 
β-lactam BLIs35,36 and from the development of avibactam.37 It 
was approved by the FDA in 2019 in combination with 
imipenem and cilastatin (a renal dehydropeptidase inhibitor 
generally associated to imipenem to prevent its degradation in 
the kidney) under the tradename Recarbrio™. The initial 
“medicinal chemistry” route used bicyclic acid 6 (from the initial 
avibactam synthesis, see Scheme 2) as the key starting material, 
onto which various amines could be coupled to get a wide range 
of derivatives.37 Later on, a route was specifically designed to 
access relebactam on multikilogram scale.  
4.2 First Synthesis. 
The first specific route to synthetize relebactam38 was described 
in details in 2011 by the team of Mangion.39 L-Pyroglutamic acid 
31 was first coupled with N-Cbz-aminopiperidine 32 and then 
protected with a Boc group to give pyrrolidinone 33 with 87% 
yield (Scheme 7). The homologation step is analogous to 
Novexel second synthesis (see Scheme 4) and the addition of 
trimethylsulfoxonium iodide in the presence of potassium tert-
butoxide gave sulfoxonium β-keto-ylide 34. Following a strategy 
initially developed by Baldwin,40 this zwitterion served as a 
carbene precursor and, in presence of an iridium complex, a N-H 
insertion reaction gave piperidine 35. Reduction of the ketone 
with LiBH4 selectively furnished cis alcohol 36 with a 12:1 
diastereomeric ratio. Activation of the alcohol by forming p-CF3-
benzenesulfonamide 37 proved crucial to favor its SN2 
displacement by N-Boc-O-benzyle hydroxylamine. After acidic 
deprotection of both N-Boc groups, hydroxylamine 38 was 
isolated in 58% yield by crystallization of its tosylate salt (21% 
over 8 steps from 31). Cyclic N-oxy-urea 39 was obtained by 
cyclization with triphosgene in the presence of phosphoric acid. 
Hydrogenolysis of the O-benzyl group  was performed with 
Pd(OH)2 in THF. Because of the concomitant cleavage of the Cbz 
group, the reaction was carried out in the presence of tert-
butylcarbonate to reprotect in situ the piperidine and form N-
hydroxy-urea 40. The sulfate group was introduced by reaction 
with SO3•pyridine, then ammonium salt 41 was isolated after 
treatment with tetra-tert-butylammonium hydrogenosulfate. 
Because relebactam is only stable in aqueous solution at pH 
between 4 and 8, extensive optimization was needed to achieve 
the deprotection of the Boc group. Eventually, by using 
HBF4•Et2O in 2,2,2-trifluoroethanol (TFE), the protecting group 
could be efficiently removed, although the need for an aqueous 
work-up complicated the process and only allowed the isolation 
of relebactam with 68% yield. The overall yield of this 13-step 
synthesis is 10%. 
Scheme 7 First synthesis of relebactam
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Scheme 8 Manufacturing route to relebactam 
4.3 Second synthesis. 
An improved manufacturing route was then developed and 
reported by the team of Miller in 2014.41 The synthetic 
sequence started with the protection of enantiopure amine 17, 
which is commercially available (1000 $/kg), by a 2-
nitrobenzenesulfonyl (2-Ns) group (Scheme 8). The 2-Ns group 
was also used to promote the lactonization of 42 into 43 and 
helped its crystallization with 99% purity (compared to the 77% 
purity of 17). Opening of the lactone with N-Boc-
aminopiperidine 32’, followed by nosylation of the alcohol, gave 
amide 44 in 98% yield. Using the lactone as a reactive 
intermediate prevented the use of coupling agents such as EDC 
and HOBt (see Scheme 7), which are expensive and generate 
unwanted by-products. Compound 45 was then obtained by 
substitution of the secondary nosylate by N-Ns-O-benzyl-
hydroxylamine, followed by cleavage of the sulfonamide using 
thioglycolic acid. Compared to the previous synthesis of N-Cbz 
analogue 38, only 6 steps are needed instead of 8 and the 
overall yield is 54% instead of 21%. Moreover, the change of 
starting material precluded the homologation step and 
therefore the use of the expensive iridium catalyst, which 
brought about extensive purification steps to reach 
pharmaceutically acceptable levels of metal traces in the final 
compound. Formation of urea 46 was achieved with 
triphosgene with 92% yield and the hydrogenolysis of the O-Bn 
group was more straightforward, as the problematic Cbz group 
was no longer used. Nevertheless, when carried out at pilot-
scale this hydrogenolysis step proved somewhat problematic 
and further refinements of this key step were recently 
disclosed. The more recent protocol uses DABCO as a catalyst 
and relies on an in situ O-silylation followed by deprotection and 
recrystallization to isolate 40.42 Eventually, it was demonstrated 
that the final deprotection of the Boc group to access 
relebactam could be achieved in a much more efficient manner 
using trimethylsilyliodide. This second route is thus only 11-step 
long and its overall yield is 42%. In 2019, an alternative 
approach to 45 using a FeCl3·6H2O/NaBH4 diasteroselective 
reduction of an oxime precursor was reported by researchers 
from Merck.43 
Scheme 9 Synthesis of key acid intermediates 47 and 6 from a relebactam precursor.
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5. Synthesis of other DBOs using the relebactam 
route 
5.1 Diverging route from a common intermediate. 
Another team of chemist from Merck recently disclosed the 
synthesis of relebactam analogues from advanced intermediate 
prepared according to Mangion’s synthetic route.44 Starting 
from amide 38 (then available in kg scale at Merck), an 
enzymatic cleavage using Amano protease P6 led to carboxylic 
acid 47 (Scheme 9). Then, N- and O-protections, followed by 
acidification allowed the isolation of the hydrochloride salt of 
ester 4 in 65% yield. Following the initial route for the synthesis 
of avibactam (see Scheme 2), bicyclic carboxyclic acid 6 was 
prepared in 90% yield. From there (or eventually from acid 47), 
coupling with substituted piperidines 48 would give amide 49 
which could then be turned into a relebactam analogues 50, 
after the standard hydrogenolysis/sulfatation/deprotection 
sequence. Only the preparation of a mono-fluoro analogue was 
described in this report. Overall, the sequence is relatively long 
to bring very minor changes to the structure of relebactam. 
5.2 Synthesis of triazole analogues. 
The route described by Mangion39 served as the basis for a 
study by the groups of Ethève-Quelquejeu and Arthur.45 
Starting from N-Boc-methyle-(S)-5-oxopyrrolidine-2-
carboxylate 51, the key piperidine 52 was obtained in 6 steps 
and 27% overall yield (Scheme 10). The 6-step sequence 
included the sulfonium homologation followed by the Ir-
catalyzed cyclization, the reduction of the resulting ketone (see 
Scheme 7) and the hydroxylamine was installed using a 
Mistunobu reaction with N-Nosyl-O-benzyl hydroxylamine, 
then both nitrogens were deprotected. The ester moiety was 
reduced to the corresponding primary alcohol, which was 
protected as a silyl ether before the triphosgene cyclization to 
give 53 with 25% yield. The TBS ether was converted into a 
primary azide in three steps to give 54 that was subjected to 
Huisgen [3+2] cycloaddition with 3-ethynylpyridine or 
trimethylsilyl acetylene to give 55a and 55b in 77% and 99% 
yield, respectively. The corresponding sodium sulfate 
derivatives 56a and 56b were then isolated with moderate 
yields in three steps. Preliminary studies showed that these 
derivatives, despite being moderate BLIs, could potentiate the 
activity of amoxicillin against mycobacteria, which could be 
attributed to inhibition of the L,D-transpeptidases by the DBOs. 
6. Synthesis of DBOs with variations of the amide 
group 
Following the advent of avibactam and relebactam, several 
companies started research programs to develop their own 
DBO BLIs. Most of those only differ at the carbonyl moiety and 
incorporate a hydrazide or an N-alkoxy-amide instead of an 
amide. Their synthesis is largely based on those previously 
disclosed, yet the best compounds display significant activities 
and are currently undergoing clinical phases.  
6.1 Nacubactam and other FPI compounds 
Nacubactam (previously known as, FPI-1459, OP0595 and 
RG6080), was initially discovered simultaneously by Meiji Seika 
Pharma46 and Fedora Pharmaceuticals (initially as NAEJA 
Pharmaceuticals),47 which formed a joint venture for its 
development in association with Roche (Roche acquired 
worldwide rights to nacubactam, except in Japan). Nacubactam 
has been undergoing clinical trials in association with 
meropenem (a carbapenem antibiotic). Like avibactam, 
nacubactam has inhibitory properties against class A and C β-
lactamases. However, contrary to avibactam, nacubactam also 
exhibits an intrinsic antibacterial activity, by inhibiting penicillin-
binding-protein-2 (PBP2), and an enhancer effect, which makes 
it promising against MBL-producing bacteria.48,49 Nacubactam 
was prepared from carboxylic acid 6 by coupling with tert-butyl 
(2-(aminooxy)ethyl)carbamate to give the corresponding amide 
57 with 84%-89% yield (Scheme 11).46,47 Subsequent 
elaboration of the sulfate moiety and deprotection of the Boc 
group led to nacubactam in 4 steps. Various alkoxy-amides and 
hydrazides, prepared following the same protocol (FPI-1465, 
FPI-1523 and FPI-1602), were also found to possess inhibitory 
properties against both SBLs (of classes A and D) and PBP2.25 
 
Scheme 10 Synthesis of triazole analogues of relebactams
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Scheme 11 Synthesis of nacubactam, zidebactam and other FPI and 
WK analogues. 
6.2 Zidebactam and congeners 
Zidebactam50 (previously known as WCK 5107) and its 
pyrrolidine analogue WK515351 were developed by Wokhardt 
using the same strategy as for nacubactam, starting from 
carboxylic acid 6 (Scheme 11). Zidebactam is undergoing clinical 
trials in combination with cefepime. Additionally, a nitrile 
analogue of avibactam was also developed: WK 4234. It was 
obtained from nitrile 58, which stemmed from primary amide 7 
by trifluoroacetic anhydride-mediated dehydration (74% 
yield).52 The latter was demonstrated to be particularly 
promising as it could not only inhibit SBLs of classes A and C but 
also oxacillinases of class D, including carbapenemases such as 
OXA-48.52 
7. Synthesis of DBOs with substituents of the 
carbon scaffold 
7.1 Synthesis of NXL-105. 
The first DBO derivatives that bore various substituents on the 
bicyclic framework were synthetized by Novexel. One of them, 
NXL-105, displayed not only a BLI profile but also antibiotic 
properties against P. aeruginosa, presumably by inhibiting 
PBPs.53 The synthesis of this tricyclic DBO, with a fused pyrazole, 
required twenty steps from 3,5-dioxopiperidine 59 (Scheme 
12). First, Knœvenagel condensation with dimethylformamide 
acetal gave 60, which underwent further condensation with 
methyl-hydrazine to form the pyrazole ring and give 61 in 83% 
yield. The ketone was then reduced and the carboxyl moiety 
installed by a t-BuLi deprotonation followed by carbon dioxide 
addition to furnish 62 (89%). Methylation of the acid was 
achieved with diazomethane and mesylation followed by 
hydroxylamine addition gave 63 in 59% yield. Deprotection of 
the Boc group followed by basic treatment set the stage for the 
formation of the bicyclic core using diphosgene and 64 was 
isolated in good yield after treatment with tartaric acid then 
DBU. The ester group was then reduced and the resulting 
primary alcohol converted into a mesylate before being 
substituted with NaN3 to give azide 65. The azide was then 
reacted with triphenylphosphine following by treatment with 
methyliodide to give a phosphonium iodide that was converted 
to methylamine 66 by heating in an aqueous sodium carbonate 
solution. From this point, the formation of sulfate 67 and the 
final isolation of NXL-105 as a sodium salt followed the “usual” 
route, plus additional protection/deprotection steps of the 
amine. The synthesis of NXL-105 is rather long (20 steps) and no 
details are provided concerning the obtention of a racemic 
mixture or a single enantiomer (and if so, how the resolution 
was carried out). Very recently, Entasis Therapeutics (a spin-out 
from AstraZeneca) patented novel pyrazolo-DBOs using an 
updated version of the NXL-105 route to access 64, which is 
then transformed into an amidine-type moiety.54 
7.2 Synthesis of IID572. 
IID572 is another type of tricyclic DBO that incorporates a 
pyrrolidone ring, which replaces the amide functional group, 
and that was developed by Novartis.55,56 A late-functionalization 
strategy was implemented starting from bicyclic acid 6 that was 
first esterified (Scheme 13). The conjugated double bond was 
then installed by an α-selenation/oxidation/elimination 
sequence to give 69 with 21% yield over three steps. After 
disappointing results using a conventional Michael addition 
reaction the methyleneamine moiety was incorporated through 
a Giese addition using an Ir-catalyzed UV-light photoredox 
process to generate the primary radical intermediate.57 
Compound 70 was obtained with a good 79% yield, yet only 10% 
of the desired diastereoisomer were isolated. Acidic cleavage of 
the Boc group set the stage for the lactamisation under basic 
condition to give 71, which was then converted into IID572 in 
four steps. This synthesis showcases how modifications of the 
carbon skeleton can be tedious, as IID572 was obtained with 
only 0.1% yield in 9 steps. IID572 did not possess any intrinsic 
antibiotic effect but exhibited a broad anti-SBL spectrum and 
could restore susceptibility to piperacillin in some piperacillin-
tazobactam resistant clinical strains.56 
7.3 Cyclopropane-fused DBO. 
In 2014, the team of Durand-Réville at AstraZeneca reported 
the synthesis and evaluation of tricyclic DBOs bearing a fused 
cyclopropyl ring.58 The hypothesis was that increasing the 
overall ring strain in the DBO scaffold could potentially improve 
the inhibition spectrum of the molecules. However, the 
formation of this strained ring required that the key 
enantioenriched monocyclic intermediate would no longer be a 
piperidine but a tetrahydropyridine, with a double bond 
suitable poised for a cyclopropanation reaction.  
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Scheme 12 Racemic synthesis of NXL-105
This led to a complete redesign of the synthetic route. The key 
enantioselective step was a dynamic kinetic asymmetric 
transformation (DYKAT) developed by the group of Trost.59 
Asymetric Pd-catalyzed opening of vinyl epoxide 72 with 
phthalimide gave allylamine 73 in near perfect yield and 
enantioselectivity (94% yield and 95% ee) on up to a 100 g scale 
(Scheme 14). The alcohol group was then protected as TBS ether 
and the phthalimide cleaved to give primary amine 74, which 
was alkylated and Boc-protected to furnish Weinreb amide 75. 
Addition of propenylmagnesium bromide (which was found to 
fare better than vinyl magnesium bromide in both the alkylation 
and the ring forming steps) led to ketone 76, which was 
submitted to Hoveyda-Grubbs catalyst to promote a ring-
closing metathesis and give key unsaturated monocyclic 
precursor 77 in 7 steps and 36% overall yield. From there, a 
stereoselective Luche reduction gave cis-allylic alcohol 78, 
which was subjected to a directed Simmons-Smith 
cyclopropanation, yielding cis-cyclopropyl-fused piperidine 79 
(50% over 2 steps). The hydroxylamine moiety was added by a 
Mitsunobu reaction (80), then the Boc group was selectively 
removed using TBSOTf (thus keeping the alcohol protected) 
followed by cleavage of the dinitro-sulfonylamide to give 81. 
The tricyclic scaffold was formed by triphosgene cyclization and 
the primary alcohol was elaborated into a primary amide in 
three steps (deprotection/oxidation/amination) to give 83. 
Finally, the usual 3-step sequence yielded 84a as a sodium salt, 
which represents a 19 steps synthetic effort with a combined 
yield of 1.8%. The other diasteroisomer 84b was also obtained 
in 12 steps from 77 by performing the cyclopropanation (Corey-
Chaikovsky) before the deprotection of the allylic alcohol.  
Scheme 13 Synthesis of IID572  
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Scheme 14 Synthesis of cyclopropane-fused DBO
The rest of the sequence is essentially similar, albeit less 
efficient (0.6% combined yield). Both compounds showed 
moderate to good inhibitory properties against SBLs of classes 
A, C and D and 84b displayed excellent aqueous stability. 
7.4 ETX2514 and analogues. 
In 2017, the team of Durand-Réville (now part of Entasis after 
the company sprung from AstraZeneca) reported the synthesis 
and evaluation of unsaturated analogues of avibactam, out of 
which ETX2514 was found to be the lead compound. As of 2019, 
ETX2514, now called Durlobactam, has successfully passed 
phase 1 and 2 of clinical trials in association with sulbactam for 
the treatment of resistant A. baumanii caused infections and 
was awarded Fast Track status by the FDA as a Qualified 
Infectious Disease Product (QIDP). All these compounds could 
be accessed thanks to the original route that was previously 
developed starting with the DYKAT reaction to access the 
cyclopropyl derivatives 84. From Weinreb amide 75, addition of 
prop-1-en-2-ylmagnesium bromide, followed by ring closing 
metathesis gave tetrahydropyridine 85 possessing a methyl 
group at the 4-position in 59% yield (Scheme 15).
Scheme 15 Synthesis of 4-methyl unsaturated DBOs 
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Scheme 16 Synthesis of ETX2514 and its relebactam-type analogue
Using essentially the same sequence described in Scheme 14 
(the hydroxylamine was introduced with an allyl instead of a 
benzyl protecting group), the 4-methyl unsaturated avibactam 
analogue 86 was obtained in 11 steps (4% combined yield). 
From 85, nitrile derivative 87 (resembling WK 4234, see Scheme 
10) could also be obtained in 12 steps (2.2% overall yield). In this 
case, the nitrile group was formed by dehydration of the 
corresponding amide using Burgess reagent. The starting point 
to access the 3-methyl regioisomer ETX2514 was compound 77 
(Scheme 16). Conjugate addition of lithium dimethylcopper was 
followed by trapping with chlorotrimethylsilane to access the 
corresponding silyl enol ether, that was subjected to a Saegusa 
type oxidation with a stoichiometric amount of Pd(OAc)2 to 
regenerate the double bond and form 88 (58%). An eleven-step 
sequence was the necessary to synthetize ETX2514 or its 
relebactam-type analogue 89. All the compounds described in 
this study are obtained through a non-optimized medicinal 
chemistry route, with some steps being rather low yielding as 
well as using expensive reagents (in addition to the Saegusa 
oxidation, the deprotection of the allyl protecting group is also 
carried out with a stoichiometric amount of a palladium 
complex). Nevertheless, compound 86 and ETX2514, displayed 
improved activity against SBLs of classes A, C and D, with 
respective IC50s of 5 and 4 nM vs. KPC-2, 76 and 14 nM vs. Amp-
C and 36 and 19 nM vs. OXA-24 (compared to 17 nM, 54 nM and 
16 µM for avibactam against those three enzymes). ETX2514 
was found to be the most promising compound, that could 
restore the activity of several antibiotics against various strains 
of Gram-negative bacteria and substantial PBP2 inhibition in E. 
coli and A. baumanii. 
8. Conclusions 
Since the development of avibactam as a potent β-lactam 
inhibitor many DBOs were successfully developed, two of them 
(avibactam and relebactam) being on the market and several 
other being at various stages of clinical trials. Considering the 
dire situation caused by the emergence of multiresistant 
bacteria, they represent a tremendous hope in the fight against 
“superbugs”. These various synthetic endeavors were mainly 
taken upon by therapeutic companies with relatively low input 
from academic groups. While many improvements in terms of 
scope and efficiency could be gained from relatively minor 
structural changes (nature of the amide group and substitution 
of the carbon framework), these changes often entailed long 
and complex synthetic sequences, as evidenced by the 
synthesis of ETX2514. One synthetic bottleneck is the formation 
of the cyclic N-oxyurea as in all cases the formation of the highly 
constrained bicyclic scaffold is achieved from an amino-
piperidine using a highly toxic triphosgene or diphosgene 
reagent (except in the industrial route to avibactam). Despite 
the importance of this key motif, alternative cyclization 
methods remain scarce,60–64 which might curb the development 
of a broader range of DBO analogues. Indeed, despite the great 
superiority of this family of BLI compared to β-lactam-based 
BLIs such as clavulanic acid or tazobactam, some unmet 
challenges remain for the design of even better compounds. 
Although DBOs can now act against all types of SBLs, none so far 
was found to be able to inhibit MBLs, although the combination 
of avibactam with aztreonam (currently in Phase III) is highly 
promising. Moreover, the interesting PBP2 properties of these 
molecules will presumably be further exploited to give birth to 
full-fledged antibiotics. Overall, in little more than 20 years, in 
parallel with the emergence of worrisome resistances in 
bacteria, the DBOs family has steadily grown to become an 
irreplaceable class of molecules that seem able to preserve our 
current antimicrobial arsenal and more molecules and new 
combinations will likely hit the market soon. 
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